Pegvisomant
Somavert · B2036-PEG
A pegylated growth hormone receptor antagonist approved for acromegaly. It blocks the receptor rather than the hormone, which is the opposite mechanism to every secretagogue in this category, and it is the reason IGF-1 rather than GH is used to follow the response.
Tracking and educational reference only, on values you enter yourself. Not medical advice or a dosing recommendation.
Half-life
~60-138 h, subcutaneous. Half-life is an educational pharmacology figure, drawn from public sources, and is not a schedule or dosing instruction.
Storage & handling
Supplied as a lyophilized powder in a single-dose vial with its own diluent; refrigerated per its label.
References
- FDA label: SOMAVERT (BLA 021106)
- Pituitary 2021: Pituitary Society update to acromegaly management guidelines
Read the source
Related in Growth Hormone
Educational reference only, compiled from public sources. Not medical advice, diagnosis, treatment, or a dosing recommendation, and not a recommendation to use any compound. Many compounds listed are research materials not approved for human use. Consult a qualified professional.